Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis

5-year Results of the GO-RAISE study

Atulya (Atul) Deodhar, Jürgen Braun, Robert D. Inman, Désirée Van Der Heijde, Yiying Zhou, Stephen Xu, Chenglong Han, Benjamin Hsu

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Objective: Assess golimumab efficacy/safety through 5 years in patients with active ankylosing spondylitis (AS). Methods: 356 patients with AS were randomly assigned to placebo, golimumab 50 mg or 100 mg every 4 weeks. At week 16, patients with inadequate response early escaped with blinded dose adjustments (placebo to 50 mg, 50 mg to 100 mg). At week 24, all patients receiving placebo crossed over to 50 mg. Blinded active therapy continued through week 104; from week 104 to week 252, the golimumab dose could be adjusted. Intentto-treat and observed efficacy data were assessed by randomised treatment groups. Results: At week 256, and with >4.5 years of golimumab, overall intent-to-treat Assessment in SpondyloArthritis international Society criteria for 20% improvement (ASAS20) and ASAS40 response rates were 66.0% (235/356) and 57.0% (203/356), respectively; Bath AS Disease Activity Index 50% improvement response was 55.9% (199/356). Observed response rates among the 255 (72%) patients who continued golimumab through week 252 were consistent, albeit somewhat higher. Among patients who increased golimumab from 50 to 100 mg, 60.6% (20/33) and 44.7% (17/38) achieved ASAS20/ASAS40 responses, respectively, following ≥2 consecutive doses of golimumab 100 mg. Golimumab safety through week 268 was similar to that through week 24 regardless of dose. Conclusions: Clinical improvements observed in patients treated with golimumab through week 24 were sustained through week 256 (5 years). Long-term golimumab safety is consistent with that of other established tumournecrosis-factor-antagonists.

Original languageEnglish (US)
Pages (from-to)757-761
Number of pages5
JournalAnnals of the Rheumatic Diseases
Volume74
Issue number4
DOIs
StatePublished - Apr 1 2015

Fingerprint

Ankylosing Spondylitis
Placebos
Safety
golimumab
Baths

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Allergy

Cite this

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis : 5-year Results of the GO-RAISE study. / Deodhar, Atulya (Atul); Braun, Jürgen; Inman, Robert D.; Van Der Heijde, Désirée; Zhou, Yiying; Xu, Stephen; Han, Chenglong; Hsu, Benjamin.

In: Annals of the Rheumatic Diseases, Vol. 74, No. 4, 01.04.2015, p. 757-761.

Research output: Contribution to journalArticle

Deodhar, Atulya (Atul) ; Braun, Jürgen ; Inman, Robert D. ; Van Der Heijde, Désirée ; Zhou, Yiying ; Xu, Stephen ; Han, Chenglong ; Hsu, Benjamin. / Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis : 5-year Results of the GO-RAISE study. In: Annals of the Rheumatic Diseases. 2015 ; Vol. 74, No. 4. pp. 757-761.
@article{4ac49d04ca6e4816b9e05296f1e340a7,
title = "Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year Results of the GO-RAISE study",
abstract = "Objective: Assess golimumab efficacy/safety through 5 years in patients with active ankylosing spondylitis (AS). Methods: 356 patients with AS were randomly assigned to placebo, golimumab 50 mg or 100 mg every 4 weeks. At week 16, patients with inadequate response early escaped with blinded dose adjustments (placebo to 50 mg, 50 mg to 100 mg). At week 24, all patients receiving placebo crossed over to 50 mg. Blinded active therapy continued through week 104; from week 104 to week 252, the golimumab dose could be adjusted. Intentto-treat and observed efficacy data were assessed by randomised treatment groups. Results: At week 256, and with >4.5 years of golimumab, overall intent-to-treat Assessment in SpondyloArthritis international Society criteria for 20{\%} improvement (ASAS20) and ASAS40 response rates were 66.0{\%} (235/356) and 57.0{\%} (203/356), respectively; Bath AS Disease Activity Index 50{\%} improvement response was 55.9{\%} (199/356). Observed response rates among the 255 (72{\%}) patients who continued golimumab through week 252 were consistent, albeit somewhat higher. Among patients who increased golimumab from 50 to 100 mg, 60.6{\%} (20/33) and 44.7{\%} (17/38) achieved ASAS20/ASAS40 responses, respectively, following ≥2 consecutive doses of golimumab 100 mg. Golimumab safety through week 268 was similar to that through week 24 regardless of dose. Conclusions: Clinical improvements observed in patients treated with golimumab through week 24 were sustained through week 256 (5 years). Long-term golimumab safety is consistent with that of other established tumournecrosis-factor-antagonists.",
author = "Deodhar, {Atulya (Atul)} and J{\"u}rgen Braun and Inman, {Robert D.} and {Van Der Heijde}, D{\'e}sir{\'e}e and Yiying Zhou and Stephen Xu and Chenglong Han and Benjamin Hsu",
year = "2015",
month = "4",
day = "1",
doi = "10.1136/annrheumdis-2014-205862",
language = "English (US)",
volume = "74",
pages = "757--761",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "4",

}

TY - JOUR

T1 - Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis

T2 - 5-year Results of the GO-RAISE study

AU - Deodhar, Atulya (Atul)

AU - Braun, Jürgen

AU - Inman, Robert D.

AU - Van Der Heijde, Désirée

AU - Zhou, Yiying

AU - Xu, Stephen

AU - Han, Chenglong

AU - Hsu, Benjamin

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Objective: Assess golimumab efficacy/safety through 5 years in patients with active ankylosing spondylitis (AS). Methods: 356 patients with AS were randomly assigned to placebo, golimumab 50 mg or 100 mg every 4 weeks. At week 16, patients with inadequate response early escaped with blinded dose adjustments (placebo to 50 mg, 50 mg to 100 mg). At week 24, all patients receiving placebo crossed over to 50 mg. Blinded active therapy continued through week 104; from week 104 to week 252, the golimumab dose could be adjusted. Intentto-treat and observed efficacy data were assessed by randomised treatment groups. Results: At week 256, and with >4.5 years of golimumab, overall intent-to-treat Assessment in SpondyloArthritis international Society criteria for 20% improvement (ASAS20) and ASAS40 response rates were 66.0% (235/356) and 57.0% (203/356), respectively; Bath AS Disease Activity Index 50% improvement response was 55.9% (199/356). Observed response rates among the 255 (72%) patients who continued golimumab through week 252 were consistent, albeit somewhat higher. Among patients who increased golimumab from 50 to 100 mg, 60.6% (20/33) and 44.7% (17/38) achieved ASAS20/ASAS40 responses, respectively, following ≥2 consecutive doses of golimumab 100 mg. Golimumab safety through week 268 was similar to that through week 24 regardless of dose. Conclusions: Clinical improvements observed in patients treated with golimumab through week 24 were sustained through week 256 (5 years). Long-term golimumab safety is consistent with that of other established tumournecrosis-factor-antagonists.

AB - Objective: Assess golimumab efficacy/safety through 5 years in patients with active ankylosing spondylitis (AS). Methods: 356 patients with AS were randomly assigned to placebo, golimumab 50 mg or 100 mg every 4 weeks. At week 16, patients with inadequate response early escaped with blinded dose adjustments (placebo to 50 mg, 50 mg to 100 mg). At week 24, all patients receiving placebo crossed over to 50 mg. Blinded active therapy continued through week 104; from week 104 to week 252, the golimumab dose could be adjusted. Intentto-treat and observed efficacy data were assessed by randomised treatment groups. Results: At week 256, and with >4.5 years of golimumab, overall intent-to-treat Assessment in SpondyloArthritis international Society criteria for 20% improvement (ASAS20) and ASAS40 response rates were 66.0% (235/356) and 57.0% (203/356), respectively; Bath AS Disease Activity Index 50% improvement response was 55.9% (199/356). Observed response rates among the 255 (72%) patients who continued golimumab through week 252 were consistent, albeit somewhat higher. Among patients who increased golimumab from 50 to 100 mg, 60.6% (20/33) and 44.7% (17/38) achieved ASAS20/ASAS40 responses, respectively, following ≥2 consecutive doses of golimumab 100 mg. Golimumab safety through week 268 was similar to that through week 24 regardless of dose. Conclusions: Clinical improvements observed in patients treated with golimumab through week 24 were sustained through week 256 (5 years). Long-term golimumab safety is consistent with that of other established tumournecrosis-factor-antagonists.

UR - http://www.scopus.com/inward/record.url?scp=84925638151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925638151&partnerID=8YFLogxK

U2 - 10.1136/annrheumdis-2014-205862

DO - 10.1136/annrheumdis-2014-205862

M3 - Article

VL - 74

SP - 757

EP - 761

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 4

ER -